Disease: systemic fungal infections

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

mycolabadmin

During the COVID-19 pandemic, fungal infections became a major health concern, especially in hospitalized patients. Treatments for COVID-19, such as steroids and immunosuppressive drugs, weakened patients’ immune systems, making them vulnerable to serious fungal infections like those caused by Candida auris. Current antifungal medications have significant side effects and many fungi are developing resistance, so scientists are urgently seeking safer and more effective antifungal treatments.

Read More »

HIV protease inhibitors restore amphotericin B activity against Candida

mycolabadmin

Researchers discovered that HIV protease inhibitors, medications commonly used to treat HIV, can significantly enhance the effectiveness of amphotericin B, a powerful antifungal drug. When combined, these medications work synergistically to kill the dangerous fungus Candida auris, reduce its ability to form protective biofilms, and lower infection levels. This finding suggests a promising new treatment strategy for multidrug-resistant fungal infections that currently pose a serious global health threat.

Read More »

The association of Yarrowia lipolytica with onychomycosis

mycolabadmin

A 20-year-old woman suffered from a persistent toenail infection that didn’t respond to several standard antifungal treatments over five years. Researchers identified the culprit as Yarrowia lipolytica, a rare yeast not previously known to cause nail infections. Testing showed this yeast was resistant to common antifungal medications the patient had received, explaining why previous treatments failed. This unusual case highlights the importance of properly identifying fungal pathogens and testing them for drug resistance before starting treatment.

Read More »
Scroll to Top